Assenagon Asset Management S.A. Purchases Shares of 606,923 uniQure N.V. $QURE

Assenagon Asset Management S.A. acquired a new stake in shares of uniQure N.V. (NASDAQ:QURE) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 606,923 shares of the biotechnology company’s stock, valued at approximately $14,524,000.

Other large investors have also recently modified their holdings of the company. JPMorgan Chase & Co. raised its holdings in uniQure by 471.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 1,807,685 shares of the biotechnology company’s stock valued at $25,199,000 after buying an additional 1,491,486 shares during the last quarter. Fred Alger Management LLC bought a new stake in uniQure in the 3rd quarter worth $75,320,000. Sofinnova Investments Inc. increased its position in shares of uniQure by 185.5% in the second quarter. Sofinnova Investments Inc. now owns 1,558,356 shares of the biotechnology company’s stock valued at $21,723,000 after acquiring an additional 1,012,585 shares during the period. Avoro Capital Advisors LLC increased its position in shares of uniQure by 22.6% in the third quarter. Avoro Capital Advisors LLC now owns 4,444,444 shares of the biotechnology company’s stock valued at $259,422,000 after acquiring an additional 819,444 shares during the period. Finally, Farallon Capital Management LLC raised its stake in shares of uniQure by 3,935.7% during the third quarter. Farallon Capital Management LLC now owns 565,000 shares of the biotechnology company’s stock valued at $32,979,000 after acquiring an additional 551,000 shares during the last quarter. Hedge funds and other institutional investors own 78.83% of the company’s stock.

uniQure Stock Performance

Shares of QURE stock opened at $15.60 on Friday. The company’s fifty day moving average price is $20.08 and its 200-day moving average price is $29.42. The stock has a market cap of $975.47 million, a PE ratio of -4.52 and a beta of 0.73. The company has a current ratio of 10.43, a quick ratio of 10.43 and a debt-to-equity ratio of 0.25. uniQure N.V. has a 12 month low of $7.76 and a 12 month high of $71.50.

uniQure (NASDAQ:QURE) last issued its quarterly earnings results on Monday, March 2nd. The biotechnology company reported ($0.56) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.93) by $0.37. uniQure had a negative net margin of 1,236.00% and a negative return on equity of 174.03%. The company had revenue of $5.57 million during the quarter, compared to analyst estimates of $4.84 million. On average, equities analysts expect that uniQure N.V. will post -3.75 EPS for the current fiscal year.

uniQure News Summary

Here are the key news stories impacting uniQure this week:

• Negative Sentiment: Multiple law firms have launched or publicized securities‑fraud investigations and class actions against uniQure, citing events around late‑Sept to Oct 2025 and urging investors to seek lead‑plaintiff status by April 13, 2026 — increasing potential litigation exposure and near‑term headline risk. QURE SHAREHOLDER ALERT: Hagens Berman Updates uniQure (QURE) Investigation
• Negative Sentiment: A securities class action has been filed and multiple firms (Bernstein Liebhard, Pomerantz, Rosen, Levi & Korsinsky, Faruqi & Faruqi, Kessler Topaz, KSF, ClaimsFiler) are soliciting plaintiffs — consolidation of suits or a lead plaintiff could accelerate discovery and settlement risk. SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against uniQure N.V
• Negative Sentiment: FDA publicly rebuked uniQure and there are allegations of “distorted” data and an FDA approval delay referenced by plaintiffs — regulatory criticism raises the chance of additional review, label or approval setbacks that would materially affect future revenue expectations. QURE ALERT: Hagens Berman Updates uniQure Investigation Following Public FDA Rebukes
• Negative Sentiment: Analyst action: Barclays lowered its price target to $25 and the shares were downgraded by at least one analyst, increasing selling pressure as forecasts and investor expectations are trimmed. Barclays Lowers uniQure (NASDAQ:QURE) Price Target to $25.00
• Negative Sentiment: Background gravity: some notices cite a prior ~49% share decline tied to the FDA delay, underscoring that litigation and regulatory developments have already driven significant investor losses and could prolong volatility. uniQure N.V. Securities Fraud Class Action Result of FDA Approval Delay and 49% Stock Decline

Insiders Place Their Bets

In other uniQure news, Director Jack Kaye sold 6,390 shares of the firm’s stock in a transaction that occurred on Friday, January 9th. The shares were sold at an average price of $27.28, for a total transaction of $174,319.20. Following the completion of the transaction, the director owned 20,439 shares of the company’s stock, valued at approximately $557,575.92. This trade represents a 23.82% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Jeannette Potts sold 3,412 shares of uniQure stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $9.06, for a total transaction of $30,912.72. Following the transaction, the insider owned 138,483 shares of the company’s stock, valued at $1,254,655.98. The trade was a 2.40% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 81,399 shares of company stock valued at $1,527,645. Insiders own 4.79% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently weighed in on QURE. Leerink Partners reiterated an “outperform” rating and set a $35.00 target price on shares of uniQure in a report on Monday, March 2nd. Royal Bank Of Canada upgraded uniQure from a “sector perform” rating to an “outperform” rating and boosted their price target for the company from $11.00 to $35.00 in a report on Monday, March 9th. TD Cowen reaffirmed a “buy” rating on shares of uniQure in a research report on Tuesday, March 3rd. Barclays cut their price objective on uniQure from $31.00 to $25.00 and set an “equal weight” rating on the stock in a research report on Monday. Finally, Wells Fargo & Company raised uniQure from an “equal weight” rating to an “overweight” rating and boosted their target price for the company from $15.00 to $60.00 in a research note on Monday, March 9th. Ten investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, uniQure has a consensus rating of “Moderate Buy” and an average target price of $42.75.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.